bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Access the interviews in their entirety at:
In an exclusive interview, Maria Zannes, President and CEO of bioAffinity, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. bioAffinity addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis through its first product, CyPath® Lung. CyPath® Lung improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. In October 2024, bioAffinity secured a U.S. Federal Supply Schedule contract for CyPath® Lung, making the test available to U.S. veterans and federal health service patients, which is expected to accelerate sales growth in the quarters ahead.
Motti Farbstein, Chief Executive Officer of Can-Fite, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's current development pipeline and upcoming milestones. Strategically positioned with multiple out-licensing deals and potential regulatory and sales milestone payments totaling over $130 million, Can-Fite has already received $20 million in upfront and milestone payments, underscoring the potential of its therapies. With advanced-stage assets targeting unmet medical needs in markets with a combined value in excess of $70 billion, Can-Fite believes that it is well positioned for the potential commercialization of its innovative therapies.
BIAF and CANF are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
--END--
SOURCE: RedChip Companies, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Roper Technologies Inc (ROP) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Total Revenue Growth: 13% increase year-over-year. Organic Revenue Growth: 7% increase. Software Bookings Growth: High teens area. Free Cash Flow Margins: 31% for the TTM period. Revenue: $1.94 billion for Q2. EBITDA: $775 million, with a margin of 39.9%. Diluted EPS: $4.87, exceeding guidance range. Free Cash Flow: $403 million, up 10% year-over-year. Net Debt to EBITDA: 2.9 times, pro forma for Subsplash at 3.1 times. Cash Balance: $242 million. Application Software Segment Revenue Growth: 17% total, 6% organic. Network Segment Revenue Growth: 6% total, 5% organic. TEP Segment Revenue Growth: 10% total, 9% organic. Full Year Revenue Growth Guidance: Increased to 13%. Full Year EPS Guidance: Increased to $19.90 to $20.05. Q3 EPS Guidance: $5.08 to $5.12. Warning! GuruFocus has detected 5 Warning Sign with ROP. Release Date: July 21, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Roper Technologies Inc (NASDAQ:ROP) reported a solid quarter with total revenue growth of 13% and organic revenue growth of 7%. The company announced the acquisition of Subsplash, a cloud-native software provider, which is expected to enhance ROP's vertical market software offerings. Free cash flow margins were impressive at 31% for the trailing twelve months, demonstrating strong cash generation capabilities. Roper Technologies Inc (NASDAQ:ROP) raised its full-year total revenue guidance and debt outlook, reflecting confidence in future performance. The company has over $5 billion in available capital for mergers and acquisitions, positioning it well for future growth opportunities. Negative Points The integration of recent acquisitions, such as ProCare, faced challenges, including leadership changes and underperformance in growth expectations. The market for some segments, like Deltek's government contracting, remains uncertain due to external factors such as government spending dynamics. The company's exposure to macroeconomic factors, although generally less sensitive, still presents potential risks in certain sectors like education and healthcare. The impact of tariffs on ROP's test business, although small, continues to be a concern that requires mitigation efforts. The competitive landscape in some markets, such as Subsplash's faith-based software, requires ongoing investment to maintain and improve growth and margin profiles. Q & A Highlights Q: Can you discuss the resilience and strength across the software segments, particularly in the context of AI and customer productivity? A: L. Neil Hunn, President and CEO, highlighted that the high teens bookings in the second quarter indicate stable market conditions. He noted that Roper's end markets, such as education, legal, and healthcare, are generally less sensitive to macroeconomic factors. The company sees significant opportunities to drive productivity gains for customers using AI tools, with businesses like Aderant already benefiting from AI-based products. Q: How are recent acquisitions, particularly those with a payments orientation, contributing to Roper's strategy? A: L. Neil Hunn explained that while some recent acquisitions like ProCare and Subsplash have a payments element, the focus remains on software-led opportunities. Payments are seen as a natural extension of the software offerings, enhancing customer stickiness and retention. The company does not have a strategic focus on payments but acknowledges the benefits they bring to the software ecosystem. Q: Did you observe any impact from tariff headlines or government spending on your business during the quarter? A: L. Neil Hunn noted that tariffs have a minimal impact on Roper's test business, estimated at $10-15 million. While there is some uncertainty in K-12 education and government contracting, the Big Beautiful Bill is expected to be a catalyst for market growth, particularly in defense spending, which should benefit Deltek. Q: Can you elaborate on the high teens bookings growth and its implications for future revenue growth? A: Jason Conley, CFO, stated that the high teens bookings growth supports Roper's second-half guidance. Aderant had its best bookings quarter, driven by AI solutions and cloud migrations. While healthcare was solid, the overall bookings activity positions the company well for future growth, with a focus on Q4 bookings impacting 2026. Q: How is AI impacting Roper's P&L, and what are the expectations for future revenue contributions? A: L. Neil Hunn mentioned that AI is providing internal productivity gains, with some businesses experiencing up to 30% improvements in R&D. While AI's direct revenue impact is currently small, the company expects it to grow significantly over time. Roper has approximately 25 AI-enabled products in development, and the company is optimistic about AI's compounding effect on growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, Rallybio Corporation (NASDAQ:RLYB) announced a definitive agreement to sell its interest in REV102 to its joint venture partner, Recursion Pharmaceuticals. The deal is valued at up to $25 million, with an upfront equity payment of $7.5 million and near-term milestone payments. REV102 is an ENPP1 inhibitor currently in preclinical development for the treatment of hypophosphatasia/HPP, which is a rare inherited disorder affecting bone and tooth mineralization. The program originated from a joint venture between Rallybio and Recursion focused on discovering and developing novel, orally available small-molecule inhibitors of ENPP1 for HPP patients. A close-up of white lab coats and protective masks in a biotechnology research laboratory. REV102, the lead candidate from this collaboration, entered IND-enabling studies in early 2025. Rallybio will also receive low single-digit royalties on all future net sales of REV102 by Recursion. Rallybio may also receive additional payments if Recursion sells the REV102 program to a third party. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company that decodes biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the US. Rallybio Corporation (NASDAQ:RLYB) is a clinical-stage biotechnology company that develops and commercializes life-transforming therapies for patients suffering from severe and rare diseases. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
‘Hold Your Horses Ahead of Earnings,' Says Top Investor About Tesla Stock
Tesla (NASDAQ:TSLA) stock has proven resilient, even as the company faces a sharp drop in sales and a deteriorating brand image – factors that would typically spell trouble for most firms. But Tesla is clearly not your average company. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. How else to explain TSLA's performance over the past few months? Despite mounting challenges, the stock has jumped 44% since its late April earnings call. Much of that momentum can be traced back to Musk's announcement during the call that he would be refocusing his attention on Tesla – a move that seemed to reassure investors. Now, with Q2 2025 results set to drop on Wednesday, July 23, the big question is whether Tesla can repeat that trick and defy the skeptics once again. Not everyone is convinced. One top investor, known by the pseudonym Deep Value Investing, is bracing for a disappointing earnings report – one that even Musk's trademark showmanship might not be able to salvage. 'I expect a weak Q2 from Tesla, which could lead to a selloff post-earnings if CEO Elon Musk fails to reignite shareholder excitement,' warns the 5-star investor, who's ranked among the top 3% of stock pickers on TipRanks. Deep Value flags a gloomy outlook from Wall Street, with analysts forecasting a double-digit drop in both revenue and EPS. While Tesla's 384,000 EV deliveries in Q2 mark a rebound from the dismal Q1, they still represent a 22% decline from Q4 2024 and a 13.5% year-over-year decrease. Adding to the uncertainty is Musk's ongoing public feud with former President Trump over the 'One Beautiful Bill' – a spat that Deep Value believes is further clouding the company's narrative. There's always a chance Musk could shift sentiment with an unexpected update on key initiatives – whether it's the Model Y, Tesla's robotaxi efforts, or Grok AI integration. But without a meaningful turnaround in EV sales, Deep Value isn't betting on it. Instead, the investor is taking a wait-and-see approach. Tesla Stock Isn't a Buy 'I prefer to stay on the sidelines and observe price action around earnings,' Deep Value concludes, assigning TSLA a Hold (i.e., Neutral) rating. (To watch Deep Value Investing's track record, click here) Wall Street seems just as conflicted. With 13 Buys, 13 Holds, and 8 Sells, Tesla's consensus rating also sits at Hold. The average price target of $298.93 suggests nearly 10% downside from current levels. (See TSLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured investor. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
